Nell Minow is Vice Chair of ValueEdge Advisors.
Not to suggest that they are making up their mind before hearing the evidence, but the House Subcommittee on the Administrative State, Regulatory Reform, and Antitrust may be suggesting their conclusion by titling the June 12 hearing “Climate Control: Decarbonization Collusion in Environmental, Social, and Governance (ESG) Investing.” Having failed to persuade anyone last year that there was some improper behavior that might be violating securities laws[1], the same forces have persuaded a subcommittee of the Judiciary Committee to try to find a violation of the antitrust laws. At this point, they are just throwing darts at a list of federal legislation to see if they can find a way to explain that it is illegal for shareholders to raise concerns about corporate strategy and conflicts of interest. When the attempt to find a fit with antitrust law fails, they may come back next year with a claim that the FDA should look into shareholder requests for information because they cause queasiness and weak knees in corporate executives.